Cardioprotective Effects of Astragalin against Myocardial Ischemia/Reperfusion Injury in Isolated Rat Heart

Daoxu Qu, Jichun Han, Huanhuan Ren, Wenxiao Yang, Xinjie Zhang, Qiusheng Zheng, and Dong Wang

1Department of Cardiac Surgery, Shandong Provincial Qianfoshan Hospital, Shandong University, Jinan 250014, China
2Key Laboratory of Xinjiang Endemic Phytomedicine Resources, Ministry of Education, Pharmacy School, Shihezi University, Shihezi 832002, China
3Shandong University of Traditional Chinese Medicine, Jinan 250014, China

Correspondence should be addressed to Qiusheng Zheng; zqsyt@sohu.com and Dong Wang; wangdong9859@sina.com

Received 29 June 2015; Accepted 15 September 2015

Academic Editor: Catherine Brenner

Copyright © 2016 Daoxu Qu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

This study aims to evaluate the cardioprotective effects of astragalin against myocardial ischemia/reperfusion (I/R) injury in isolated rat heart. The cardioprotective effects of astragalin on myocardial I/R injury were investigated on Langendorff apparatus. Adult male Sprague-Dawley rats were randomly divided into five groups. The results showed that astragalin pretreatment improved myocardial function. Compared with I/R group, lactate dehydrogenase (LDH) and creatine kinase (CK) activities in coronary flow decreased in astragalin pretreatment groups, whereas superoxide dismutase (SOD) activity and glutathione/glutathione disulfide (GSH/GSSG) ratio significantly increased. The levels of malondialdehyde (MDA), intracellular reactive oxygen species (ROS), tumor necrosis factor-α (TNF-α), and interleukin-6 (IL-6) decreased in astragalin-treated groups. The infarct size (IS) and apoptosis rate in hearts from astragalin-treated groups were lower than those in hearts from the I/R group. Western blot analysis also revealed that astragalin preconditioning significantly reduced Bax level, whereas Bcl-2 was increased in the myocardium. Therefore, astragalin exhibited cardioprotective effects via its antioxidant, antiapoptotic, and anti-inflammatory activities.

1. Introduction

Ischemic heart disease is a leading cause of death worldwide. Myocardial ischemia/reperfusion (I/R) injury is an unavoidable phenomenon during treatment of ischemic heart diseases; and such phenomenon can result in reperfusion arrhythmias, transient mechanical dysfunction, myocardial stunning, and other disorders [1, 2]. Therefore, in the clinical setting, myocardial I/R injury is considered a major factor that affects patient outcome.

Studies show that the pathophysiology mechanisms behind myocardial I/R injury are related to many factors, such as massive free radical production, changes in hemorheology, intracellular calcium overload, increased inflammation, myocardial necrosis, and apoptosis [3, 4]. In addition, a substantial amount of evidence from animal experiments and clinical studies supports the idea that reactive oxygen species (ROS) play an important role in I/R injury and are considered targets for therapeutic interventions [5]. During reperfusion, robust ROS generation beyond the catalytic process of antioxidants (e.g., superoxide dismutase (SOD)) could result in the following: production of excessive amount of hydroxyl radicals, which have a high potential to damage cellular structures, enzymes, or channel proteins on the cellular membrane and can cause damage to DNA and RNA [6, 7]. Likewise, reducing inflammatory responses during reperfusion after ischemic insult has been shown to be beneficial in numerous studies [8]. Thus, various interventions that target these mechanisms have been proposed to eliminate I/R-induced myocardial damage.

Among these therapies, pharmacological preconditioning is widely used because of its simplicity, convenience,
and relative cost. A vast number of pharmacological agents can afford cardioprotection in experimental models and clinical studies, such as exenatide [9, 10]. Recently, the use of traditional Chinese herbal treatments against myocardial I/R injury has become popular because of their unique efficacy against oxidative stress and their limited adverse reactions. For example, flavonoid compounds, which are widely expressed in plants, have important physiological functions, such as protecting the heart from I/R injury through various mechanisms [11, 12]. Our previous studies also demonstrated that flavonoid extracts exhibit cardioprotective effects on myocardial I/R injury in isolated rat hearts via anti-inflammatory, antioxidative, and antiapoptotic activities [13, 14].

Astragalin (kaempferol-3-O-glucoside) is a flavonoid that is extracted from leaves of persimmon, Rosa agrestis, or green tea seeds. Numerous preclinical studies have shown that astragalin has a wide range of pharmacological activities, including antioxidative, anti-inflammatory, and antitumor activities; astragalin can ameliorate apoptosis effects [15–17]. Finally, we hypothesized that the antioxidative, anti-inflammatory, and antiapoptotic effects of astragalin may also be involved in the prevention of I/R injury. In this study, we aimed to evaluate the cardioprotective effects of astragalin.

2. Materials and Methods

2.1. Animals. Adult male Sprague-Dawley rats (260–290 g) were purchased from Xingdu Medicine University Medical Laboratory Animal Center (SDXX 2011-004). The rats were maintained under standard laboratory conditions at 25 ± 2°C, relative humidity of 60 ± 15%, and natural light-dark photoperiod. All experimental procedures were approved by the Institutional Animal Care and Use Committee of the National Institute Pharmaceutical Education and Research.

2.2. Test Compound and Reagents. Astragalin (purity ≥98%) was purchased from Chengdu Must Bio-Technology Co., Ltd. (Sichuan, China) and dissolved in dimethyl sulfoxide (Sigma) before use. The dimethyl sulfoxide concentration in the working solutions was <0.1%, which had no effect on the present study. Terminal deoxynucleotidyl nick-end labeling (TUNEL) assay was conducted using in situ cell death detection kit (POD, Roche, Germany). All other reagents were of standard biochemical quality and were obtained from commercial suppliers.

2.3. Study Groups and Establishment of Animal Model. The rats were randomly divided into five groups: control group, I/R group, and astragalin groups (pretreated with 5, 10, and 20 μmol/L of astragalin).

The establishment of model was described previously [13]. The rats were anesthetized with chloral hydrate (0.35 g/kg) through intraperitoneal injection and then provided with 250 U/kg heparin through sublingual venous injection to prevent coagulation. The hearts were quickly excised and immediately immersed in 40 mL of ice-cold Krebs-Henseleit (K–H; pH 7.4) solution prepared in the laboratory. This solution contains 118 mM NaCl, 1.2 mM KH$_2$PO$_4$, 4.7 mM KCl, 1.7 mM CaCl$_2$, 1.2 mM MgSO$_4$, 20 mM sodium acetate, and 10 mM glucose. Finally, the hearts were quickly mounted on a Langendorff apparatus via the aorta. The hearts were perfused at constant pressure (75 mmHg) throughout the experiment at 37°C with K–H buffer containing 95% O$_2$ and 5% CO$_2$. A water-filled latex balloon coupled to a pressure transducer (Statham) was inserted into the left ventricular cavity via the left auricle to record pressure. Ventricular end-diastolic pressure (VEDP) was adjusted between 5 and 12 mmHg.

The control group was perfused for 90 min (stabilization period). The I/R group was subjected to 15 min of zero-flow global ischemia and 45 min of reperfusion after stabilization. Astragalin-treated groups were stabilized for 20 min, treated with K–H buffer solution containing astragalin (5, 10, and 20 μmol/L) for 10 min and then subjected to global ischemia for 15 min and reperfusion for 45 min.

The hemodynamic parameters (including the left ventricular developed pressure (LVPD), the maximum up/down rate of left ventricular pressure (±dp/dt max), heart rate (HR), and coronary flow (CF)) were continuously monitored using a computer-based data acquisition system (PC PowerLab with Chart 5 software, 4S AD Instruments). At the end of reperfusion, the hearts were stored at –80°C for further analysis.

2.4. Measurement of Cellular Injury. The levels of lactate dehydrogenase (LDH) and creatine kinase (CK) released were measured as degree of cardiac injury. LDH and CK kits (Nanjing Jiancheng Biological Product, Nanjing, China) were used to measure the levels of LDH and CK. The samples were collected from the coronary effluent before ischemia at 20 min of reperfusion and at 45 min of reperfusion.

2.5. Evaluation of Myocardial Infarct Size (IS). Myocardial IS was evaluated by triphenyltetrazolium chloride (TTC) staining as previously described [13]. Briefly, the heart was frozen at −20°C for 30 min and then cut into five slices along the transverse direction. Each piece was 2 mm thick. The slices were incubated in 1% TTC buffer at 37°C for 30 min and then fixed in 10% formaldehyde solution for 24 h. The slices were imaged using a digital camera. Image-Pro Plus 7.0 (Media Cybernetics, Wyoming, USA) was used to measure the IS area. Red parts indicated nonischemic area, whereas white parts indicated ischemic area. IS percentage was calculated using the following equation: %Infarct volume = (infarct volume/total volume of slice) × 100.

2.6. Assay of Oxidative Stress. At the end of treatments, the heart ventricles were preserved at −80°C for subsequent analysis. The frozen ventricles were crushed to a powder using liquid nitrogen-chilled tissue pulverizer. For tissue analysis, a weighed amount of frozen tissues was homogenized in the appropriate buffer using a microcentrifuge tube homogenizer. Corresponding ELISA kits (Nanjing Jiancheng Biological Product, Nanjing, China) were prepared to analyze the activity of SOD and the content of malondialdehyde (MDA) and the ratio of glutathione and glutathione disulfide (GSH/GSSG). Intracellular ROS generation was measured with the sensitive fluorescent probe 2′,7′-dichlorofluorescein.
diacetate (DCFH-DA) according to the instructions of commercial kits (Nanjing Jiancheng Biological Product, Nanjing, China). Briefly, cardiomyocytes were dispersed from another six rats’ hearts using digestion buffer, washed with KB solution, and then incubated with 5 μmol DCFH-DA for 20 min. The fluorescence intensity was measured using a fluorospectrophotometer with 488 nm excitation and 525 nm emission filters.

2.11. Statistical Analysis. Data were presented as mean ± SD. Student’s t-test results were evaluated by two-way analysis of variance. Statistical analysis was performed using SPSS 17.0 (IBM SPASS, International Business Machines Corporation, Armonk, NY, USA). p < 0.05 was considered statistically significant.

3. Results

3.1. Astragalin Improved the Recovery of LVDP, ±dp/dt max, and CF. We evaluated cardiac function by monitoring hemodynamic parameters. The concentration of astragalin (5, 10, and 20 μmol/L) used in the experiments was determined according to preliminary experiments. As shown in Table 1, compared with the I/R group, a significant recovery of LVDP, ±dp/dt max, and CF was apparent in the astragalin-treated groups, and the group treated with 10 μmol/L of astragalin showed better recovery of cardiac function. No significant difference in HR was found between the control and pre-treated groups.

3.2. Astragalin Attenuated I/R-Induced Enzyme Release. The heart effluents were collected at selected times to measure the release of LDH and CK as degree of myocardial injury. As shown in Table 2, after 15 min of ischemia followed by 20 and 45 min of reperfusion, elevated LDH and CK activities were detected in the I/R group. Pretreatment with astragalin significantly reduced the release of LDH and CK induced by I/R (p < 0.05).

3.3. Astragalin Reduced I/R-Induced IS. Representative images of heart sections stained with TTC are shown in Figure 1. IS significantly increased in the I/R group (52.78% ± 3.98%). On the contrary, astragalin preconditioning reduced I/R-induced myocardial IS. Astragalin preconditioning at 5, 10, and 20 μmol/L significantly reduced I/R-induced myocardial IS by 28.22% ± 2.79%, 23.67% ± 1.98%, and 24.36% ± 1.97%, respectively (Figure 1(f)).

3.4. Astragalin Alleviated Oxidative Stress. As shown in Figure 2, pretreatment with astragalin significantly decreased MDA level (Figure 2(a)) (**P < 0.01) and increased SOD activity (Figure 2(b)) and GSH/GSSG ratio (Figure 2(c)) compared with the I/R group. Significant reductions in intracellular ROS levels were also observed in the astragalin groups compared with the I/R group (Figure 2(d), *P < 0.05).

3.5. Astragalin Reduced Myocardial Structure Injury. Hematoxylin and eosin (HE) stain was used to evaluate the changes in the morphological structure of myocardial tissue in different groups (Figure 3). The myocardial structures of the control group (Figure 3(a)) were as follows: muscle fibers were...
Table 1: Effect of astragalin on cardiac function in rats subjected to I/R (values are presented as mean ± SD, n = 8).

| Physical index | 15 min | Reperfusion (%) | 30 min | 45 min |
|----------------|--------|-----------------|--------|--------|
| LVDP           |        |                 |        |        |
| Control        | 97.41 ± 4.49 | 94.89 ± 6.04 | 94.11 ± 6.85 | |
| I/R            | 40.93 ± 3.83** | 47.61 ± 4.17** | 49.19 ± 2.44** | |
| 5 μmol/L astragalin | 50.16 ± 5.25* | 64.82 ± 5.30 | 62.23 ± 6.87 | |
| 10 μmol/L astragalin | 84.97 ± 3.53** | 81.67 ± 6.37** | 79.92 ± 5.82** | |
| 20 μmol/L astragalin | 68.88 ± 5.24* | 66.45 ± 4.19 | 63.15 ± 3.53 | |
| +dP/dt_max     |        |                 |        |        |
| Control        | 104.18 ± 13.85 | 103.12 ± 14.17 | 103.03 ± 11.86 | |
| I/R            | 41.90 ± 4.10** | 52.54 ± 4.30** | 52.17 ± 4.86** | |
| 5 μmol/L astragalin | 52.51 ± 5.34* | 60.79 ± 4.12 | 63.34 ± 5.13 | |
| 10 μmol/L astragalin | 83.70 ± 4.36** | 85.05 ± 4.96** | 80.58 ± 5.78** | |
| 20 μmol/L astragalin | 67.96 ± 3.07* | 65.62 ± 4.68 | 62.38 ± 4.67 | |
| −dP/dt_max     |        |                 |        |        |
| Control        | 96.85 ± 3.61 | 94.96 ± 2.94 | 94.17 ± 0.94 | |
| I/R            | 49.56 ± 7.51** | 56.98 ± 3.91** | 56.10 ± 5.80** | |
| 5 μmol/L astragalin | 59.15 ± 3.36 | 56.30 ± 5.61 | 57.52 ± 5.39 | |
| 10 μmol/L astragalin | 85.77 ± 4.71** | 84.49 ± 6.86** | 81.17 ± 7.51** | |
| 20 μmol/L astragalin | 64.72 ± 4.19 | 63.34 ± 4.05 | 60.69 ± 4.35 | |
| CF             |        |                 |        |        |
| Control        | 107.69 ± 4.35 | 108.15 ± 4.94 | 106.47 ± 7.19 | |
| I/R            | 57.69 ± 4.74** | 58.15 ± 4.16** | 56.47 ± 2.53** | |
| 5 μmol/L astragalin | 63.60 ± 3.65 | 66.54 ± 3.22 | 68.62 ± 5.79 | |
| 10 μmol/L astragalin | 108.36 ± 7.41** | 108.15 ± 10.98** | 106.24 ± 13.35** | |
| 20 μmol/L astragalin | 72.11 ± 7.88* | 70.19 ± 1.88 | 70.20 ± 4.46 | |
| HR             |        |                 |        |        |
| Control        | 98.42 ± 2.62 | 98.67 ± 4.24 | 100.34 ± 2.61 | |
| I/R            | 84.10 ± 8.58 | 86.39 ± 4.67 | 86.79 ± 6.99 | |
| 5 μmol/L astragalin | 96.75 ± 3.27 | 94.67 ± 2.78 | 93.67 ± 2.41 | |
| 10 μmol/L astragalin | 94.04 ± 1.66 | 95.45 ± 5.04 | 89.27 ± 8.24 | |
| 20 μmol/L astragalin | 89.04 ± 6.48 | 90.25 ± 6.22 | 91.14 ± 3.14 | |

Left ventricular developed pressure (LVDP), the maximum up rate of left ventricular pressure (+dP/dt_max), the maximum down rate of left ventricular pressure (−dP/dt_max), coronary flow (CF), and heart rate (HR). *p < 0.01 and **p < 0.05 compared with the control group; ***p < 0.01 and ****p < 0.05 compared with the I/R group.

Table 2: Effect of astragalin on levels of LDH and CK in coronary flow (values are presented as mean ± SD, n = 8).

| Physical index | Before ischemia | 20 min | 45 min |
|----------------|-----------------|--------|--------|
| LDH (U/L)      |                 |        |        |
| Control        | 10.65 ± 0.24    | 10.26 ± 0.15 | 10.13 ± 0.30 |
| I/R            | 10.64 ± 0.14    | 26.81 ± 0.19** | 24.48 ± 0.30** |
| 5 μmol/L astragalin | 11.81 ± 0.05    | 20.41 ± 0.13 | 19.49 ± 0.16 |
| 10 μmol/L astragalin | 12.46 ± 0.33    | 12.56 ± 0.21** | 10.67 ± 0.17** |
| 20 μmol/L astragalin | 12.84 ± 0.42    | 17.94 ± 0.54* | 15.72 ± 0.25* |
| CK (U/L)       |                 |        |        |
| Control        | 29.03 ± 0.53    | 25.68 ± 0.50 | 26.18 ± 0.46 |
| I/R            | 29.89 ± 2.74    | 352.06 ± 19.80** | 131.14 ± 8.32** |
| 5 μmol/L astragalin | 26.56 ± 2.55    | 265.95 ± 16.67 | 106.74 ± 13.02 |
| 10 μmol/L astragalin | 27.96 ± 1.97    | 237.31 ± 15.27* | 89.82 ± 12.15* |
| 20 μmol/L astragalin | 24.09 ± 2.39    | 248.64 ± 13.99* | 93.97 ± 16.08* |

*P < 0.01 and **P < 0.05 compared with control group; ***P < 0.01 and ****P < 0.05 compared with the I/R group.
Figure 1: Effect of astragalin on I/R-induced IS. (a–e) Representative illustrations of heart sections stained with TTC (the section in the middle of the picture is apex cordis). (a) Heart sections in the control group, there are almost no IS. (b) Heart sections in the I/R group. (c–e) Heart sections in astragalin groups (pretreated with 5, 10, and 20 μmol/L of astragalin). (f) Quantitative analysis of percentage of IS (values are presented as mean ± SD n = 6). ##P < 0.01 compared with the control group; **P < 0.01 compared with the I/R group.

3.6. Astragalin Weakened I/R-Induced Cardiomyocyte Apoptosis. The apoptosis percentage is shown in Figure 4. Compared with the I/R group, the number of apoptotic cells (manifested as a marked appearance of dark brown cell nuclei) decreased in all groups pretreated with astragalin (Figures 4(c)–4(e)). The group pretreated with 10 μmol/L of astragalin showed significantly reduced I/R-induced myocardial structure turbulence. However, the groups pretreated with 5 μmol/L of astragalin (Figure 3(c)) indicated no significant difference compared with the I/R group.
Figure 2: (a–c) Effect of astragalin on cardiac contents of MDA, SOD activity, and GSH/GSSG ratio in rats subjected to I/R (values are presented as mean ± SD, n = 8). (d) Effect of astragalin on intracellular ROS levels (fold above control) (data are presented as mean ± SD, n = 6). **p < 0.01 compared with the control group; *p < 0.05 and **p < 0.01 compared with the I/R group.

(Figure 4(d)) showed an obviously reduced number of apoptotic cells (**p < 0.01).

3.7. Astragalin Reduced Inflammatory Response. Inflammation is an important mechanism underlying myocardial I/R injury. The presence of inflammatory cytokines (TNF-α and IL-6) is associated with I/R. ELISA results showed that pretreatment with astragalin reduced the levels of TNF-α and IL-6 induced by I/R (p < 0.05). As is shown in Figure 5, the activity of TNF-α in the group pretreated with 10 μmol/L astragalin (101.45 ± 7.04 pg/mL) was significantly lower (p < 0.01) than that in the I/R group (233.71 ± 16.98 pg/mL) (Figure 5(a)). The content of IL-6 increased from 78.94 ± 4.73 pg/mL in the group pretreated with 10 μmol/L astragalin to 107.70 ± 4.15 pg/mL in the I/R group (Figure 5(b)) (p < 0.01).

3.8. Effect of Astragalin Preconditioning on the Expression of Bcl-2 and Bax. The expression of Bcl-2 and Bax proteins extracted by Western blot analysis from the same part in the left ventricular cavity of the rats is shown in Figure 6. The expression of the antiapoptotic protein Bcl-2 was significantly decreased and that of the proapoptotic protein Bax was significantly increased in the I/R group compared with the control group (Figure 6(a)). Astragalin preconditioning increased Bcl-2 expression (Figure 6(b)) (p < 0.05) compared with the I/R group. Astragalin preconditioning (especially at 10 μmol/L) inhibited the increase of Bax (Figure 6(c)) (p < 0.05).

4. Discussion

In this study, we found that astragalin showed promising cardioprotective effects against acute I/R injury by (1) improving
cardiac function recovery; (2) reducing intracellular oxidation status; (3) reducing myocardial IS; (4) and inhibiting myocardial apoptosis.

Studies have suggested that oxidative stress is among the major factors contributing to I/R injury [18]. Physiologically, ROS becomes hydrogen peroxide via SOD [2] or is reduced by antioxidant molecules, such as GSH [19]. However, when the amount of ROS is beyond the capacity of the abovementioned enzymes, oxidative stress occurs. This change may cause unsaturated fat to undergo lipid peroxidation, thereby aggravating myocardial damage. Reducing oxidative stress is an advantageous strategy to alleviate I/R injury.

According to previous studies, the production of ROS promoted by I/R include superoxide anions (O$_2^-$), hydroxyl free radicals (HO''), hydrogen peroxide (H$_2$O$_2$), and nitric oxide (NO) [20]. But astragalin is just proved to act as antioxidants on cells [17], not on tissue or in vivo. Now that ROS formation is also the end result of several different oxidant-producing pathways (such as the mitochondria, xanthine oxidase (XO), and nicotinamide adenine dinucleotide phosphate-oxidase (NOX)) [20], therefore the intracellular ROS level is tested as indicators of oxidation. MDA is a lipid peroxidation end product, which has been used to assess oxygen injury of I/R myocardium [21]. The levels of SOD activity and GSH/GSSG rate are used to evaluate tissue peroxidative injury. In this study, astragalin was shown to reduce the myocardial I/R injury-induced intracellular ROS generation. Our results also demonstrated that astragalin

Figure 3: (a–e) Representatively histopathological observations of the heart (bar = 100 μm). HE staining (×200). (a) Normal architecture of myocardium in the control group. (b) Architecture of myocardium in the I/R group. (c–e) Architecture of myocardium in the astragalin groups (pretreated with 5, 10, and 20 μmol/L of astragalin).
could increase SOD activity and GSH/GSSG rate and reduce MDA content. Thus this finding suggested that the enhancement of antioxidase activity and inhibition of peroxidation of free radicals in the myocardium might be at least partially involved in the cardioprotective mechanisms of astragalin in response to myocardial I/R injury.

Myocardial I/R injury is considered an inflammatory condition [22]. The inflammatory cytokines IL-6 and TNF-α are involved in I/R injury [23, 24]. They are both important mediators of inflammation including stimulation of the acute phase response; however, overproduction of these cytokines can result in severe proinflammatory reactions.
Figure 5: Astragalin reduced proinflammatory cytokine levels in heart tissue of rats subjected to 15 min ischemia followed by 45 min reperfusion. (a-b) Measurement of IL-6 and TNF-α in heart tissue by ELISA (values are presented as mean ± SD, n = 8). # p < 0.01 compared with the control group; * p < 0.05 and ** p < 0.01 compared with the I/R group.

Figure 6: Western blotting analysis of Bcl-2 and Bax. β-actin was used to demonstrate equal protein loading. (a) Representative images are shown. (b-c) Quantitative measurement of the Western blot (% control) in different groups (data are presented as mean ± SD, n = 6). # p < 0.01 compared with the control group; * p < 0.05 and ** p < 0.01 compared with the I/R group.
and aggravating inflammation [25]. To investigate whether a relationship exists between the anti-inflammatory and cardioprotective effects of astragalin, we examined the effect of astragalin on IL-6 and TNF-α induced by I/R injury. In this study, we observed that astragalin preconditioning reduced the concentrations of IL-6 and TNF-α compared with I/R models. Therefore, we deduce that inflammatory cytokine reduction by astragalin may contribute to its cardioprotective effects after reperfusion.

Reperfusion of the ischemic myocardium can result in heart dysfunction and cardiomyocyte apoptosis [26, 27]. The present results showed that astragalin preconditioning significantly improved $\frac{\Delta p}{\Delta t}$, CF, and LVDP after reperfusion, indicating that astragalin preconditioning could improve the contractile and diastolic functions of the I/R myocardium. The large reduction of infarct size and release of enzymes (CK and LDH) at the end of reperfusion indicated that astragalin preconditioning had a significant effect on cardioprotection.

Apoptosis is a mainstay of tissue damage secondary to reperfusion injury after short ischemia. Several studies have suggested that the upregulation of several antiapoptotic factors including the Bcl-2 gene and downregulation of proapoptotic genes such as Bax play an important role in salvage of ischemic tissue [28, 29]. By examining the Western blot and TUNEL staining, we observed that astragalin preconditioning decreased Bax expression and increased Bcl-2 expression. The number of apoptotic cells decreased in the groups pretreated with astragalin. These results indicate that astragalin exerted remarkable cardioprotective effects against myocardial I/R injury through the effects of antiapoptosis. The antiapoptosis activity may be related to the Bcl-2 family. Studies show that Bcl-2 family members regulate apoptosis by modulating mitochondrial membrane permeability and contribute to myocardial preservation by decreasing susceptibility to mitochondrial permeability transition pore (mPTP) opening [30, 31]. Wang et al. [32] suggests that mPTP is the target of Bcl-2. Thus the mPTP may not be the direct target of astragalin. Further research is required to investigate the relationship between mPTP and the effects of astragalin.

At the same time our results show that the effects of astragalin were not strictly dose-dependent on the model of isolated rate heart. A tentative inference on this result is that the high dose of astragalin may have some side effects, such as prooxidant. Astragalin contains multiple hydroxyl radicals and a phenol structure in the B ring. Studies show that these structures can also cause damage to DNA and other side effects [33, 34]. Further research is required to investigate these in larger, longer-term studies.

In conclusion, we provided the first evidence that pretreatment with astragalin showed significant cardioprotective effects during I/R injury. The effects included inhibition of myocardial oxidative damage, decreased infarct volume and cardiomyocyte apoptosis, reduced inflammatory response, and improved heart function. Therefore, the cardioprotective effects of astragalin may be associated with its antioxidant, antiapoptotic, and anti-inflammatory activities. Further studies are needed to confirm whether astragalin can be used in a clinical setting.

### Conflicts of Interests

The authors declare that they have no financial conflict of interests.

### Acknowledgment

This study was supported by the Science and Technology Development Planning of Shandong Province (2014GSF118090) to Dong Wang.

### References

1. A. Sekikawa, B. Y. Horiuchi, D. Edmundowicz et al., “A ‘natural experiment’ in cardiovascular epidemiology in the early 21st century,” *Heart*, vol. 89, no. 3, pp. 255–257, 2003.

2. L. M. Buja and P. Weerasinghe, ”Unresolved issues in myocardial reperfusion injury,” *Cardiovascular Pathology*, vol. 19, no. 1, pp. 29–35, 2010.

3. Y.-M. Lee, P.-Y. Cheng, S.-Y. Chen, M.-T. Chung, and J.-R. Sheu, “Wogonin suppresses arrhythmias, inflammatory responses, and apoptosis induced by myocardial ischemia/reperfusion in rats,” *Journal of Cardiovascular Pharmacology*, vol. 58, no. 2, pp. 133–142, 2011.

4. S. Sanada, I. Komuro, and M. Kitakaze, “Pathophysiology of myocardial reperfusion injury: preconditioning, postconditioning, and translational aspects of protective measures,” *American Journal of Physiology—Heart and Circulatory Physiology*, vol. 301, no. 5, pp. H1723–H1741, 2011.

5. K. R. Bainey and P. W. Armstrong, “Clinical perspectives on reperfusion injury in acute myocardial infarction,” *American Heart Journal*, vol. 167, no. 5, pp. 637–645, 2014.

6. J. A. Ruiz-Ginés, S. López-Ongil, M. González-Rubio, L. González-Santiago, M. Rodríguez-Puyol, and D. Rodríguez-Puyol, “Reactive oxygen species induce proliferation of bovine aortic endothelial cells,” *Journal of Cardiovascular Pharmacology*, vol. 35, no. 1, pp. 109–113, 2000.

7. P. Markowski, O. Boehm, L. Goelz et al., “Pre-conditioning with synthetic CpG-oligonucleotides attenuates myocardial ischemia/reperfusion injury via IL-10 up-regulation,” *Basic Research in Cardiology*, vol. 108, no. 5, article 376, 2013.

8. Y. M. Tsutsumi, T. Yokoyama, Y. Horiikawa, D. M. Roth, and H. H. Patel, “Reactive oxygen species trigger ischemic and pharmacological postconditioning: in vivo and in vitro characterization,” *Life Sciences*, vol. 81, no. 15, pp. 1223–1227, 2007.

9. L. Timmers, J. P. S. Henriques, D. P. V. de Kleijn et al., “Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury,” *Journal of the American College of Cardiology*, vol. 53, no. 6, pp. 501–510, 2009.

10. B. Ibanez, S. Prat-González, W. S. Speid et al., “Early metoprolol administration before coronary reperfusion results in increased myocardial salvage: analysis of ischemic myocardium at risk using cardiac magnetic resonance,” *Circulation*, vol. 115, no. 23, pp. 2909–2916, 2007.

11. X.-N. Xu, Z.-R. Niu, S.-B. Wang et al., “Effect and mechanism of total flavonoids of bugloss on rats with myocardial ischemia and reperfusion injury,” *Yao Xue Xue Bao*, vol. 49, no. 6, pp. 875–881, 2014.

12. Y. Ma, Y. Wang, Y. Gao, Y. Fu, and J. Li, “Total flavonoids from Ganshаниban (Herba Hyperici Attenuati) effect the expression of Cal-α1C and KATP-Kir6.1 mRNA of the myocardial cell membrane in myocardial ischemia-reperfusion arrhythmia rats,”
F.-C. Liu, H.-I. Tsai, and H.-P. Yu, “Organ-protective effects of natural phenolics,” *Journal of Traditional Chinese Medicine*, vol. 34, no. 3, pp. 357–361, 2014.

J. Han, D. Wang, B. Yu et al., “Cardioprotection against ischemia/reperfusion by licochalcone B in isolated rat hearts,” *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 134862, 11 pages, 2014.

M. Zhou, L. Liu, W. Wang et al., “Role of licochalcone C in cardioprotection against ischemia/reperfusion injury of isolated rat heart via antioxidant, anti-inflammatory, and anti-apoptotic activities,” *Life Sciences*, vol. 132, pp. 27–33, 2015.

M.-S. Kim and S.-H. Kim, “Inhibitory effect of astragalin on expression of lipopolysaccharide-induced inflammatory mediators through NF-κB in macrophages,” *Archives of Pharmacal Research*, vol. 34, no. 12, pp. 2101–2107, 2011.

O. Burmistrova, J. Quintana, J. G. D´ıaz, and F. Est´evez, “Astragaline-heptacetate-induced cell death in human leukemia cells is dependent on caspases and activates the MAPK pathway,” *Cancer Letters*, vol. 309, no. 1, pp. 71–77, 2011.

I.-H. Cho, J.-H. Gong, M.-K. Kang et al., “Astragalin inhibits airway eosinophil induction and epithelial apoptosis through modulating oxidative stress-responsive MAPK signaling,” *BMC Pulmonary Medicine*, vol. 14, article 122, 2014.

S. Ekeløf, S. E. Jensen, J. Rosenberg, and I. Gögünur, “Reduced oxidative stress in STEMI patients treated by primary percutaneous coronary intervention and with antioxidant therapy: a systematic review,” *Cardiovascular Drugs and Therapy*, vol. 28, no. 2, pp. 173–181, 2014.

A. Toth, R. Halmosi, K. Kovacs et al., “Akt activation induced by an antioxidant compound during ischemia-reperfusion,” *Free Radical Biology and Medicine*, vol. 35, no. 9, pp. 1051–1063, 2003.

F.-C. Liu, H.-I. Tsai, and H.-P. Yu, “Organ-protective effects of red wine extract, resveratrol, in oxidative stress-mediated reperfusion injury,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID 568634, 15 pages, 2015.

M. K. Ozer, H. Parlakpinar, Y. Cigremis, M. Ucar, N. Vardi, and A. Acet, “Ischemia-reperfusion leads to depletion of glutathione content and augmentation of malondialdehyde production in the rat heart from overproduction of oxidants: can caffeic acid phenethyl ester (CAPE) protect the heart?” *Molecular and Cellular Biochemistry*, vol. 273, no. 1-2, pp. 169–175, 2005.

L. Timmers, G. Pasterkamp, V. C. de Hoog, F. Arslan, Y. Appelman, and D. P. V. de Kleijn, “The innate immune response in reperfused myocardium,” *Cardiovascular Research*, vol. 94, no. 2, pp. 276–283, 2012.

B. H. M. Heijn, I. H. Straatsburg, N. D. Padilla, G. J. Van Mierlo, C. E. Hack, and T. M. Van Gulik, “Inhibition of classical complement activation attenuates liver ischaemia and reperfusion injury in a rat model,” *Clinical and Experimental Immunology*, vol. 143, no. 1, pp. 15–23, 2006.

K. Watanabe, C. Iwashara, H. Nakayama et al., “Sevoflurane suppresses tumour necrosis factor-α-induced inflammatory responses in small airway epithelial cells after anoxia/reoxygenation,” *British Journal of Anaesthesia*, vol. 110, no. 4, pp. 637–645, 2013.

F. Li, W. Wang, Y. Cao et al., “Inhibitory effects of astragalin on lipopolysaccharide-induced inflammatory response in mouse mammary epithelial cells,” *Journal of Surgical Research*, vol. 192, no. 2, pp. 573–581, 2014.

N. Hu, M. Dong, and J. Ren, “Hydrogen sulfide alleviates cardiac contractile dysfunction in an Akt2-knockout murine model of insulin resistance: Role of mitochondrial injury and apoptosis,” *Oxidative Medicine and Cellular Longevity*, vol. 2015, Article ID e0118834, 2015.

C. Wang, D. A. Neff, J. G. Krolkowski et al., “The influence of B-cell lymphoma 2 protein, an antiapoptotic regulator of mitochondrial permeability transition pore (MPTP) opening in ischemia-damaged mitochondria,” *PLoS ONE*, vol. 10, no. 3, Article ID e0118834, 2015.

A. Simić, D. Manojlović, D. Šegan, and M. Todorović, “Electrochemical behavior and antioxidant and prooxidant activity of natural phenolics,” *Molecules*, vol. 12, no. 10, pp. 2327–2340, 2007.